You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What is Dovato?

Dovato is a treatment for human immunodeficiency virus (HIV) infection.

Dovato is made up of two different medicines, called dolutegravir and lamivudine, combined in one tablet.

Dovato is used to treat HIV in adults and adolescents over 12 years old who weigh at least 40 kg.
Dovato does not cure HIV infection; it keeps the amount of virus in your body at a low level. This helps maintain the number of CD4 cells in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.

Safety Information

For safety information on Dovato please see the Dovato patient information leaflet (PIL) available at Dovato 50 mg/300 mg film-coated tablets (medicines.ie)

Patient Information

This information is specifically for patients that have been prescribed Dovato by a Healthcare Professional registered in Ireland.
I am a patient

References:

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the product package leaflet. You can also report side effects directly to HPRA Pharmacovigilance on their website: www.hpra.ie. By reporting side effects, you can help provide more information on the safety of this medicine.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.